Skip to main content
GPCR
NASDAQ Life Sciences

Structure Therapeutics Q2 Loss Widens to $106M as R&D Costs Surge

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$52.62
Mkt Cap
$3.591B
52W Low
$15.8
52W High
$94.9
52W Position info
233% above low
Off High info
45% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

GPCR has more than doubled off its 52-week low of $15.8.

Summary

Structure Therapeutics reported a Q2 net loss of $106.16 million, driven by a jump in operating expenses to $118.63 million as clinical trial activity ramped up. The company dosed the first patients in Phase 3 trials for its lead obesity drug, aleniglipron, and disclosed a $1.3 billion cash runway through 2028. Topline 72-week data from the ACCESS OLE study is expected in Q3 2026, with a new combination GLP-1/amylin agonist trial starting in Q4. The widening loss reflects the cost of advancing a pipeline that recently showed up to 16.2% weight loss in Phase 2b, but the cash position provides ample funding to reach key milestones without near-term dilution risk.

At the time of this announcement, GPCR was trading at $52.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $15.80 to $94.90. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

GPCR - Latest Insights

GPCR
Nov 09, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $21.50 info
Change: +$0.090 (+0.42%) info
Market Cap: $1.527B info
GPCR
Nov 09, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $21.50 info
Change: +$0.090 (+0.42%) info
Market Cap: $1.527B info
GPCR
Sep 22, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $36.78
Real-time Price: $21.50 info
Change: -$15.28 (-42%) info
Market Cap: $1.527B info
GPCR
Sep 08, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.60
Real-time Price: $21.50 info
Change: -$26.10 (-55%) info
Market Cap: $1.527B info
GPCR
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $47.50
Real-time Price: $21.50 info
Change: -$26.00 (-55%) info
Market Cap: $1.527B info